secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0001493152-24-041702
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Mira Pharma reports Ketamir-2 beats Gabapentin and Pregabalin in preclinical neuropathic pain study
--------------------------------------------------------------------------------

- Ketamir-2 demonstrated significantly greater efficacy than FDA-approved Gabapentin (Neurontin) and Pregabalin (Lyrica) in preclinical neuropathic pain models.
- IND application submission remains on track for end of 2024; Phase I trials expected to begin Q1 2025; Phase II by late 2025.
- Exploring government funding opportunities to support planned PTSD clinical trials.
- Additional preclinical studies focused on chemotherapy-induced and diabetic neuropathy are actively underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224041702/0001493152-24-041702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224041702/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-041702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer